Michael Yee
Stock Analyst at Jefferies
(3.74)
# 788
Out of 4,712 analysts
79
Total ratings
42.59%
Success rate
11.38%
Average return
Main Sectors:
Stocks Rated by Michael Yee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALXO ALX Oncology Holdings | Downgrades: Hold | $12 → $2 | $1.62 | +23.46% | 4 | Dec 19, 2024 | |
| KOD Kodiak Sciences | Upgrades: Buy | $20 | $9.98 | +100.40% | 3 | Dec 9, 2024 | |
| BIIB Biogen | Downgrades: Hold | $250 → $180 | $151.31 | +18.96% | 5 | Dec 9, 2024 | |
| VRTX Vertex Pharmaceuticals | Upgrades: Buy | $500 → $550 | $408.76 | +34.55% | 4 | Dec 9, 2024 | |
| AMGN Amgen | Maintains: Buy | $380 | $262.65 | +44.68% | 5 | Nov 12, 2024 | |
| DNLI Denali Therapeutics | Maintains: Buy | $40 → $45 | $20.61 | +118.34% | 2 | Nov 1, 2024 | |
| MRNA Moderna | Maintains: Hold | $65 → $55 | $40.13 | +37.05% | 8 | Oct 15, 2024 | |
| MBX MBX Biosciences | Initiates: Buy | $35 | $20.07 | +74.39% | 1 | Oct 8, 2024 | |
| ORKA Oruka Therapeutics | Initiates: Buy | $40 | $19.01 | +110.42% | 1 | Sep 13, 2024 | |
| AXON Axon Enterprise | Initiates: Buy | $385 | $610.98 | -36.99% | 4 | Jul 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $1.4 → $10 | $2.76 | +262.32% | 3 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $32 | $14.14 | +126.31% | 2 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $16 → $3 | $2.33 | +28.76% | 2 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $75 → $30 | $26.59 | +12.82% | 2 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $3 → $1 | $0.45 | +123.21% | 8 | Oct 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $8 → $20 | $44.46 | -55.02% | 3 | Oct 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $63 → $75 | $41.15 | +82.26% | 1 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $2.38 | +1,160.50% | 1 | Nov 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $65 | $29.18 | +122.76% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $75 → $45 | $0.58 | +7,658.62% | 2 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $40 → $30 | $2.28 | +1,215.79% | 4 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $15 → $30 | $15.14 | +98.15% | 3 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $120 | $15.16 | +691.56% | 2 | Nov 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $70 → $75 | $19.77 | +279.36% | 2 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $15.01 | +99.87% | 1 | Sep 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $77 | $10.76 | +615.61% | 2 | Nov 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $94.11 | - | 3 | Jan 26, 2018 |
ALX Oncology Holdings
Dec 19, 2024
Downgrades: Hold
Price Target: $12 → $2
Current: $1.62
Upside: +23.46%
Kodiak Sciences
Dec 9, 2024
Upgrades: Buy
Price Target: $20
Current: $9.98
Upside: +100.40%
Biogen
Dec 9, 2024
Downgrades: Hold
Price Target: $250 → $180
Current: $151.31
Upside: +18.96%
Vertex Pharmaceuticals
Dec 9, 2024
Upgrades: Buy
Price Target: $500 → $550
Current: $408.76
Upside: +34.55%
Amgen
Nov 12, 2024
Maintains: Buy
Price Target: $380
Current: $262.65
Upside: +44.68%
Denali Therapeutics
Nov 1, 2024
Maintains: Buy
Price Target: $40 → $45
Current: $20.61
Upside: +118.34%
Moderna
Oct 15, 2024
Maintains: Hold
Price Target: $65 → $55
Current: $40.13
Upside: +37.05%
MBX Biosciences
Oct 8, 2024
Initiates: Buy
Price Target: $35
Current: $20.07
Upside: +74.39%
Oruka Therapeutics
Sep 13, 2024
Initiates: Buy
Price Target: $40
Current: $19.01
Upside: +110.42%
Axon Enterprise
Jul 17, 2024
Initiates: Buy
Price Target: $385
Current: $610.98
Upside: -36.99%
Mar 27, 2024
Upgrades: Buy
Price Target: $1.4 → $10
Current: $2.76
Upside: +262.32%
Mar 22, 2024
Maintains: Buy
Price Target: $28 → $32
Current: $14.14
Upside: +126.31%
Mar 15, 2024
Downgrades: Hold
Price Target: $16 → $3
Current: $2.33
Upside: +28.76%
Dec 8, 2023
Downgrades: Hold
Price Target: $75 → $30
Current: $26.59
Upside: +12.82%
Oct 25, 2023
Downgrades: Hold
Price Target: $3 → $1
Current: $0.45
Upside: +123.21%
Oct 25, 2023
Upgrades: Buy
Price Target: $8 → $20
Current: $44.46
Upside: -55.02%
Jan 6, 2023
Upgrades: Buy
Price Target: $63 → $75
Current: $41.15
Upside: +82.26%
Nov 15, 2021
Initiates: Buy
Price Target: $30
Current: $2.38
Upside: +1,160.50%
Mar 2, 2021
Initiates: Buy
Price Target: $65
Current: $29.18
Upside: +122.76%
Mar 2, 2021
Downgrades: Hold
Price Target: $75 → $45
Current: $0.58
Upside: +7,658.62%
Feb 12, 2021
Downgrades: Hold
Price Target: $40 → $30
Current: $2.28
Upside: +1,215.79%
Feb 12, 2021
Upgrades: Buy
Price Target: $15 → $30
Current: $15.14
Upside: +98.15%
Nov 6, 2020
Downgrades: Hold
Price Target: $120
Current: $15.16
Upside: +691.56%
Oct 12, 2020
Upgrades: Buy
Price Target: $70 → $75
Current: $19.77
Upside: +279.36%
Sep 14, 2020
Initiates: Buy
Price Target: $30
Current: $15.01
Upside: +99.87%
Nov 8, 2018
Assumes: Buy
Price Target: $77
Current: $10.76
Upside: +615.61%
Jan 26, 2018
Upgrades: Buy
Price Target: n/a
Current: $94.11
Upside: -